Fedora Pharmaceuticals Inc. Unveils Details of Antibiotic Resistance Program in 10 Posters at 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
8/27/2013 8:59:51 AM
EDMONTON, Alberta, Aug. 27, 2013 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. today announced that the Company and its collaborators will be presenting 10 posters at the upcoming Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). These presentations provide details of the Company's investigational broad-spectrum beta-lactamase inhibitor, FPI-1465. FPI-1465 is undergoing pre-clinical testing as an adjunct to antibiotics for the treatment of patients with difficult-to-treat, resistant bacterial infections. ICAAC is being held in Denver, CO September 10-13, 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by